Methylphenidate

(Redirected from Ritalin)
Summary sheet: Methylphenidate
Methylphenidate
Methylphenidate.svg
Chemical Nomenclature
Common names Methylphenidate, Concerta, Methylin, Ritalin, Equasym XL
Substitutive name Methylphenidate
Systematic name Methyl 2-phenyl-2-piperidin-2-ylacetate
Class Membership
Psychoactive class Stimulant
Chemical class Phenidate
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



⇣ Oral
Dosage
Bioavailability 11-52%[1]
Threshold 5 mg
Light 10 - 20 mg
Common 20 - 40 mg
Strong 40 - 60 mg
Heavy 60 mg +
Duration
Total 4 - 6 hours
Onset 20 - 60 minutes
Come up 20 - 60 minutes
Peak 1.5 - 2.5 hours
Offset 1 - 2 hours
After effects 2 - 6 hours



⇣ Insufflated
Dosage
Threshold 5 mg
Light 10 - 15 mg
Common 15 - 30 mg
Strong 30 - 60 mg
Heavy 60 mg +
Duration
Total 2 - 4 hours
Onset 5 - 20 minutes
Come up 15 - 40 minutes
Peak 30 - 45 minutes
Offset 2 - 4 hours
After effects 1 - 4 hours






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Alcohol
MXE
Dissociatives
DXM
MDMA
Stimulants
25x-NBOMe
25x-NBOH
Tramadol
MAOIs

Methylphenidate (also known as MPH, MPD, and the trade names Ritalin, Concerta, and Methylin, among others) is a classical potent stimulant substance of the phenidate class. It is the parent compound of the substituted phenidates, a family of stimulants that includes ethylphenidate, isopropylphenidate, and others. The mechanism of action involves increasing concentrations of the neurotransmitters dopamine and norepinephrine.

It was first synthesized in 1944 and was approved for medical use in the United States in 1955. It was originally sold by Swiss company CIBA (now Novartis).[2] It is approved for treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy. It is often used by students with or without ADHD as a cognitive enhancer and study aid.

Subjective effects include stimulation, focus enhancement, motivation enhancement, increased libido, appetite suppression, and euphoria. It is usually taken orally, but can also be insufflated or administered rectally. The effects are comparable to those of amphetamine; however, it is reported to produce less euphoria and generally have less recreational value. Some users also report it produces a stronger comedown relative to amphetamine especially with high doses.

It has moderate abuse potential. Chronic use (i.e. high dose, repeat administration) is associated with compulsive redosing, escalating tolerance, and psychological dependence. It is highly advised to use harm reduction practices if using this substance.

History and culture

 

This History and culture section is a stub.

As a result, it may contain incomplete or wrong information. You can help by expanding it.

Methylphenidate was first licensed by the U.S. Food and Drug Administration (FDA) in 1955 for treating what was then known as "hyperactivity."[citation needed] Although it was prescribed to patients as early as 1960, it only became heavily prescribed in the 1990s when the diagnosis of ADHD itself became more widely accepted.[3][4]

It was estimated that the number of doses of methylphenidate used globally in 2013 increased by 66% compared to 2012.[5] In 2019, it was the 51st most commonly prescribed medication in the United States, with more than 14 million prescriptions.[6][7] It is available as a generic medication.

Chemistry

Methylphenidate is a synthetic molecule of the substituted phenethylamine and substituted phenidate classes. It contains a phenethylamine core featuring a phenyl ring bound to an amino (-NH2) group through an ethyl chain.

It is structurally similar to amphetamine, featuring a substitution at Rα which is incorporated into a piperidine ring ending at the terminal amine of the phenethylamine chain. Additionally, it contains a methyl acetate bound to Rβ of its structure.

Dexmethylphenidate

Methylphenidate is a chiral compound, presumably produced as a racemic mixture. It has an enantiopure also sold as a pharmaceutical; the dextrorotary enantiopure is known as "dexmethylphenidate" and is commonly sold as Focalin and Focalin XR.

Four isomers of methylphenidate are possible, since the molecule has two chiral centers. One pair of threo isomers and one pair of erythro are distinguished, from which primarily d-threo-methylphenidate exhibits the pharmacologically desired effects.[8]

The erythro diastereomers are pressor amines, a property not shared with the threo diastereomers. When the drug was first introduced it was sold as a 4:1 mixture of erythro:threo diastereomers, but it was later reformulated to contain only the threo diastereomers. "TMP" refers to a threo product that does not contain any erythro diastereomers, i.e. (±)-threo-methylphenidate. Since the threo isomers are energetically favored, it is easy to epimerize out any of the undesired erythro isomers.

The drug that contains only dextrorotatory methylphenidate is sometimes called d-TMP, although this name is only rarely used and it is much more commonly referred to as dexmethylphenidate, d-MPH, or d-threo-methylphenidate. A review on the synthesis of enantiomerically pure (2R,2'R)-(+)-threo-methylphenidate hydrochloride has been published.[9]

 
Dexmethylphenidate in skeletal formula

Pharmacology

Methylphenidate primarily acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It is most active at modulating levels of dopamine and, to a lesser extent, norepinephrine.[10] Methylphenidate binds to and blocks dopamine transporters and norepinephrine transporters.[11]

While both amphetamine and methylphenidate are dopaminergic, it should be noted that their methods of action are somewhat distinct. Specifically, methylphenidate is a dopamine reuptake inhibitor while amphetamine is both a releasing agent and reuptake inhibitor of dopamine and norepinephrine. Each of these drugs have a corresponding effect on norepinephrine which are weaker than their effects on dopamine.

Methylphenidate's mechanism of action at dopamine-norepinephrine release is still debated, but is fundamentally different from most other phenethylamine derivatives as methylphenidate is thought to increase general firing rate, whereas amphetamine reduces firing rate and reverses the flow of the monoamines via TAAR1 activation.[12][11][13][14]

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.


Physical effects
 

Cognitive effects
 

After effects
 

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

 

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

 
Radar plot showing relative physical harm, social harm, and dependence of methylphenidate[18]

A toxic dose of methylphenidate is considered to be more than 2 mg/kg or 60 mg of an immediate-release formulation, or more than 4 mg/kg or 120 mg of an intact extended-release formulation.[19] In the majority of cases in one study, methylphenidate overdose was asymptomatic or characterized by minor symptoms even in children under age 6.

However, a significant amount of patients (31%) in the study developed symptoms typical of stimulant overdose, most commonly tachycardia, agitation, and paradoxically lethargy.[20] In the 2012 National Poison Data System report, methylphenidate exposure was reported 9,787 times, with 1,609 reporting no adverse effects, 1,009 reporting mild effects, 662 reporting moderate effects, 33 reporting major symptoms, and no cases resulting in death.[21]

It is strongly advised to use harm reduction practices if using this substance.

Dependence and abuse potential

In terms of its tolerance, methylphenidate can be used multiple days in a row for extended periods of time and is often prescribed to be used in this way. Tolerance to many of the effects of methyphenidate develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects.[22]

In the case of acute (i.e. one-off) exposure, it generally takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption).[citation needed] Methylphenidate presents cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of methyphenidate all stimulants will have a reduced effect."[citation needed]

As with other stimulants, the chronic use of methylphenidate can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Methylphenidate has some potential for abuse due to its action on dopamine transporters. Methylphenidate, like other stimulants, increases dopamine levels in the brain. However, at therapeutic doses this increase is slow and thus euphoria only rarely occurs even when it is administered intravenously.[23] The abuse and addiction potential of methylphenidate is therefore significantly lower than other dopaminergic stimulants.[23][24]

The abuse potential is increased when methylphenidate is crushed and insufflated (snorted) or injected.[25]. It should be noted that due to the fillers in the pill, however, that this can be harmful to the nasal cavities, and intravenous use can cause emphysema (a lower respiratory tract disease, aka ritalin lung when caused by Ritalin tablets). The intravenous use of methylphenidate, commonly marketed as Ritalin and widely used as a stimulant drug in the treatment of attention deficit hyperactivity disorder, can lead to emphysematous changes known as Ritalin lung.

. The primary source of methylphenidate for abuse is the diversion from legitimate prescriptions rather than illicit synthesis. Those who use methylphenidate medicinally generally take it orally as instructed while intranasal and intravenous are the preferred means for recreational use.[26]

Psychosis

Main article: Stimulant psychosis

Chronic use (i.e. high dose, repeat dosing) may increase the risk of psychosis.[25][27] The safety profile of short-term methylphenidate therapy has been well-established, with short-term clinical trials revealing a very low incidence (0.1%) of methylphenidate-induced psychosis at therapeutic dose levels.[28]

Psychotic symptoms from methylphenidate can include hearing voices, visual hallucinations, urges to harm oneself, severe anxiety, mania, disinhibition, paranoid and grandiose delusions, confusion, emotional suppression, increased aggression, and irritability.

Combination with alcohol

Methylphenidate (when taken orally) has a low bioavailability around 30%. If taken with alcohol (ethanol), blood plasma levels of dexmethylphenidate are increased by up to 40%.[29] A metabolite called ethylphenidate is also formed.[30]

Alcohol induced dose dumping (AIDD)

 

Alcohol may be dangerous to combine with modified-release dosage medications.

This dose dumping effect is an unintended rapid release of large amounts of a given drug, when administered through a modified-release dosage while co-ingesting ethanol.[31] This is considered a pharmaceutical disadvantage due to the high risk of causing drug-induced toxicity by increasing the absorption and serum concentration above the therapeutic window of the drug. The best way to prevent this interaction is by avoiding the co-ingestion of both substances or using specific controlled-release formulations that are resistant to AIDD.

In vitro data suggest that some extended-release stimulants may experience dose dumping in the presence of alcohol. This is a concern because the ADHD patient population is at risk for alcohol abuse. The potential for dose dumping when taking extended-release stimulants with alcohol could lead to unintended and dangerous side effects for those with ADHD.[32]

An example of an extended-release formula includes the methylphenidate medication brand Concerta.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • 25x-NBOMe & 25x-NBOH - 25x compounds are highly stimulating and physically straining. Combinations with Methylphenidate should be strictly avoided due to the risk of excessive stimulation and heart strain. This can result in increased blood pressure, vasoconstriction, panic attacks, thought loops, seizures, and heart failure in extreme cases.
  • Alcohol - Combining alcohol with stimulants can be dangerous due to the risk of accidental over-intoxication. Stimulants mask alcohol's depressant effects, which is what most people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects will be left unopposed, which can result in blackouts and severe respiratory depression. If mixing, the user should strictly limit themselves to only drinking a certain amount of alcohol per hour.
  • DXM - Combinations with DXM should be avoided due to its inhibiting effects on serotonin and norepinephrine reuptake. There is an increased risk of panic attacks and hypertensive crisis, or serotonin syndrome with serotonin releasers (MDMA, methylone, mephedrone, etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
  • MDMA - Any neurotoxic effects of MDMA are likely to be increased when other stimulants are present. There is also a risk of excessive blood pressure and heart strain (cardiotoxicity).
  • MXE - Some reports suggest combinations with MXE may dangerously increase blood pressure and increase the risk of mania and psychosis.
  • Dissociatives - Both classes carry a risk of delusions, mania and psychosis, and these risk may be multiplied when combined.
  • Stimulants - Methylphenidate may be dangerous to combine with other stimulants like cocaine as they can increase one's heart rate and blood pressure to dangerous levels.
  • Tramadol - Tramadol is known to lower the seizure threshold[33] and combinations with stimulants may further increase this risk.
  • MDMA - The neurotoxic effects of MDMA may be increased when combined with other stimulants.

Legal status

Internationally, methylphenidate is a Schedule II drug under the Convention on Psychotropic Substances.[35]

  • Australia: Methylphenidate is a 'Schedule 8' controlled substance. Such drugs must be kept in a lockable safe before being handed out and possession without prescription carries hefty fines and even imprisonment.[36]
  • Austria: Methylphenidate is legal for medical use under the AMG (Arzneimittelgesetz Österreich) and illegal when sold or possessed without a prescription under the SMG (Suchtmittelgesetz Österreich).[citation needed]
  • Canada: Methylphenidate is listed in Schedule III of the Controlled Drugs and Substances Act (along with LSD, psychedelic mushrooms, and mescaline).[37] It is illegal to possess without a prescription pursuant to Part G (section G.01.002) of the Food and Drug Regulations under the Food and Drugs Act.
  • Germany: Methylphenidate is a controlled substance under Anlage III of the BtMG. It can only be prescribed on a narcotic prescription form.[38]
  • New Zealand: Methylphenidate is a 'Class B2 controlled substance'. Unlawful possession is punishable by six-month prison sentence and the distribution of it is punishable by a 14-year sentence.[citation needed]
  • Sweden: Methylphenidate is a List II controlled substance with recognized medical value. Possession without a prescription is punishable by up to three years in prison.[39]
  • Switzerland: Methylphenidate is a controlled substance specifically named under Verzeichnis A. Medicinal use is permitted.[40]
  • Turkey: Methylphenidate is a 'red prescription' only substance[41] and illegal when sold or possessed without a prescription.[citation needed]
  • United Kingdom: Methylphenidate is a controlled 'Class B' substance. Possession without a prescription carries with it a sentence of up to 5 years and/or an unlimited fine and supplying it is 14 years and/or an unlimited fine.[42]
  • United States: Methylphenidate is classified as a Schedule II controlled substance, the designation used for substances that have a recognized medical value but present a high potential for abuse.[citation needed]

It is a widespread myth that methylphenidate could lead to false-positives for amphetamine in drug screenings. However, there was found no immunoassay cross reactivity in laboratory study.[43]

See also

External links

Literature

  • Leonard, B. E., McCartan, D., White, J., & King, D. J. (2004). Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Human Psychopharmacology: Clinical and Experimental, 19(3), 151-180. https://doi.org/10.1002/hup.579

References

  1. ↑ "https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/483/original/Health_Canada_-_Ritalin.PDF?1556050208"
  2. ↑ Lange, K. W., Reichl, S., Lange, K. M., Tucha, L., Tucha, O. (December 2010). "The history of attention deficit hyperactivity disorder". ADHD Attention Deficit and Hyperactivity Disorders. 2 (4): 241–255. doi:10.1007/s12402-010-0045-8. ISSN 1866-6116. 
  3. ↑ Diller, L. H. (1999). Running on ritalin: a physician reflects on children, society, and performance in a pill. Bantam Books. ISBN 9780553379068. 
  4. ↑ Lange, K. W., Reichl, S., Lange, K. M., Tucha, L., Tucha, O. (2010). "The history of attention deficit hyperactivity disorder". Attention Deficit and Hyperactivity Disorders. 2 (4): 241–255. doi:10.1007/s12402-010-0045-8. ISSN 1866-6116. 
  5. ↑ "Narcotics monitoring board reports 66% increase in global consumption of methylphenidate". The Pharmaceutical Journal. 2015. doi:10.1211/PJ.2015.20068042. ISSN 2053-6186. 
  6. ↑ "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021. 
  7. ↑ "Methylphenidate - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021. 
  8. ↑ Heal, D. J., Pierce, D. M. (2006). "Methylphenidate and its Isomers: Their Role in the Treatment of Attention-Deficit Hyperactivity Disorder Using a Transdermal Delivery System". CNS Drugs. 20 (9): 713–738. doi:10.2165/00023210-200620090-00002. ISSN 1172-7047. 
  9. ↑ Prashad, M. (July 2001). <379::AID-ADSC379>3.0.CO;2-4 "Approaches to the Preparation of Enantiomerically Pure (2R,2′R)-(+)-threo-Methylphenidate Hydrochloride". Advanced Synthesis & Catalysis. 343 (5): 379–392. doi:10.1002/1615-4169(200107)343:5<379::AID-ADSC379>3.0.CO;2-4. ISSN 1615-4150. 
  10. ↑ Heal, D. J., Pierce, D. M. (1 September 2006). "Methylphenidate and its Isomers". CNS Drugs. 20 (9): 713–738. doi:10.2165/00023210-200620090-00002. ISSN 1179-1934. 
  11. ↑ 11.0 11.1 Iversen, L. (January 2006). "Neurotransmitter transporters and their impact on the development of psychopharmacology". British Journal of Pharmacology. 147 (Suppl 1): S82–S88. doi:10.1038/sj.bjp.0706428. ISSN 0007-1188. 
  12. ↑ Volkow, N. D., Wang, G. J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y. S., Hitzemann, R., Pappas, N. (October 1998). "Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate". The American Journal of Psychiatry. 155 (10): 1325–1331. doi:10.1176/ajp.155.10.1325. ISSN 0002-953X. 
  13. ↑ Focalin XR review | http://www.pharma.us.novartis.com/product/pi/pdf/focalinXR.pdf
  14. ↑ Concerta Xl slow release | http://www.medicines.org.uk/emc/medicine/8382/SPC/Concerta#PHARMACOLOGICAL_PROPSSPC
  15. ↑ 15.0 15.1 Montastruc, F., Montastruc, G., Montastruc, J.-L., Revet, A. (22 June 2016). "Cardiovascular safety of methylphenidate should also be considered in adults". BMJ: i3418. doi:10.1136/bmj.i3418. ISSN 1756-1833. 
  16. ↑ 16.0 16.1 16.2 16.3 16.4 Leonard, B. E., McCartan, D., White, J., King, D. J. (April 2004). "Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects". Human Psychopharmacology: Clinical and Experimental. 19 (3): 151–180. doi:10.1002/hup.579. ISSN 0885-6222. 
  17. ↑ Nestler, E. J., Hyman, S. E., Malenka, R. C. (2009). Molecular neuropharmacology: a foundation for clinical neuroscience (2nd ed ed.). McGraw-Hill Medical. ISBN 9780071481274. 
  18. ↑ Nutt, D., King, L. A., Saulsbury, W., Blakemore, C. (24 March 2007). "Development of a rational scale to assess the harm of drugs of potential misuse". The Lancet. 369 (9566): 1047–1053. doi:10.1016/S0140-6736(07)60464-4. ISSN 0140-6736. 
  19. ↑ Scharman, E. J., Erdman, A. R., Cobaugh, D. J., Olson, K. R., Woolf, A. D., Caravati, E. M., Chyka, P. A., Booze, L. L., Manoguerra, A. S., Nelson, L. S., Christianson, G., Troutman, W. G., American Association of Poison Control Centers (November 2007). "Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management". Clinical Toxicology (Philadelphia, Pa.). 45 (7): 737–752. doi:10.1080/15563650701665175. ISSN 1556-3650. 
  20. ↑ White, S. R., Yadao, C. M. (1 December 2000). "Characterization of Methylphenidate Exposures Reported to a Regional Poison Control Center". Archives of Pediatrics & Adolescent Medicine. 154 (12): 1199. doi:10.1001/archpedi.154.12.1199. ISSN 1072-4710. 
  21. ↑ 2012 Annual Report of the American Association of Poison Control Centers ’ National Poison Data System (NPDS): 28th Annual Report | https://aapcc.s3.amazonaws.com/pdfs/annual_reports/2012_NPDS_Annual_Report.pdf
  22. ↑ Swanson, J., Gupta, S., Guinta, D., Flynn, D., Agler, D., Lerner, M., Williams, L., Shoulson, I., Wigal, S. (September 1999). "Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children". Clinical Pharmacology and Therapeutics. 66 (3): 295–305. doi:10.1016/S0009-9236(99)70038-X. ISSN 0009-9236. 
  23. ↑ 23.0 23.1 Volkow, N. D., Wang, G. J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y. S., Dewey, S. L., Hitzemann, R., Gifford, A. N., Pappas, N. R. (January 1999). "Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high"". The Journal of Pharmacology and Experimental Therapeutics. 288 (1): 14–20. ISSN 0022-3565. 
  24. ↑ Volkow, N. D., Swanson, J. M. (November 2003). "Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD". American Journal of Psychiatry. 160 (11): 1909–1918. doi:10.1176/appi.ajp.160.11.1909. ISSN 0002-953X. 
  25. ↑ 25.0 25.1 Morton, W. A., Stockton, G. G. (October 2000). "Methylphenidate Abuse and Psychiatric Side Effects". Primary Care Companion to The Journal of Clinical Psychiatry. 2 (5): 159–164. ISSN 1523-5998. 
  26. ↑ Klein-Schwartz, W. (April 2002). "Abuse and toxicity of methylphenidate:". Current Opinion in Pediatrics. 14 (2): 219–223. doi:10.1097/00008480-200204000-00013. ISSN 1040-8703. 
  27. ↑ Spensley, J., Rockwell, D. A. (20 April 1972). "Psychosis during Methylphenidate Abuse". New England Journal of Medicine. 286 (16): 880–881. doi:10.1056/NEJM197204202861607. ISSN 0028-4793. 
  28. ↑ Ritalin & Ritalin-SR Prescribing Information | http://www.pharma.us.novartis.com/product/pi/pdf/ritalin_ritalin-sr.pdf
  29. ↑ Patrick, K., Straughn, A., Minhinnett, R., Yeatts, S., Herrin, A., DeVane, C., Malcolm, R., Janis, G., Markowitz, J. (March 2007). "Influence of Ethanol and Gender on Methylphenidate Pharmacokinetics and Pharmacodynamics". Clinical pharmacology and therapeutics. 81 (3): 346–353. doi:10.1038/sj.clpt.6100082. ISSN 0009-9236. 
  30. ↑ Markowitz, J. S., DeVane, C. L., Boulton, D. W., Nahas, Z., Risch, S. C., Diamond, F., Patrick, K. S. (June 2000). "Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol". Drug Metabolism and Disposition: The Biological Fate of Chemicals. 28 (6): 620–624. ISSN 0090-9556. 
  31. ↑ D'Souza S, Mayock S, Salt A (December 2017). "A review of in vivo and in vitro aspects of alcohol-induced dose dumping". AAPS Open (in English). 3 (1). doi:10.1186/s41120-017-0014-9  . ISSN 2364-9534. 
  32. ↑ Jain, R; Stark, JG (September 2016). "Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications". Postgraduate medicine. 128 (7): 672–81. doi:10.1080/00325481.2016.1218259. PMID 27467139. 
  33. ↑ Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. eISSN 1937-6995. ISSN 1556-9039. OCLC 163567183. 
  34. ↑ Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210  . eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647. 
  35. ↑ "Green List: Annex to the annual statistical report on psychotropic substances (form P)" (PDF). Archived from the original (PDF) on 31 August 2012. (1.63 MB) 23rd edition. August 2003. International Narcotics Board, Vienna International Centre. Retrieved 2 March 2006.
  36. ↑ "POISONS STANDARD DECEMBER 2019". Office of Parliamentary Counsel. Retrieved December 24, 2019. 
  37. ↑ "SCHEDULE III". Department of Justice. Archived from the original on April 16, 2011. Retrieved December 24, 2019. 
  38. ↑ Anlage III BtMG - Einzelnorm 
  39. ↑ Narkotikastrafflag (1968:64) (NSL), Lagen.nu 
  40. ↑ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  41. ↑ KIRMIZI REÇETEYE TABİ İLAÇLAR | https://www.titck.gov.tr/storage/Archive/2019/contentFile/K%C4%B1rm%C4%B1z%C4%B1%20Re%C3%A7eteye%20Tabi%20%C4%B0la%C3%A7lar%2005072019_ebcc7e92-6661-4983-870a-fe8983a9c2b7.pdf
  42. ↑ Misuse of Drugs Act 1971 
  43. ↑ Breindahl, Torben; Hindersson, Peter (2012). "Methylphenidate is Distinguished from Amphetamine in Drug-of-Abuse Testing". Journal of Analytical Toxicology. 36 (7): 538–539. doi:10.1093/jat/bks056. ISSN 0146-4760. 


Retrieved from ‘https://psychonautwiki.org/w/index.php?title=Methylphenidate&oldid=162122’